Inflammation in Obesity-Related HFpEF

Journal of the American College of Cardiology, Год журнала: 2024, Номер 84(17), С. 1646 - 1662

Опубликована: Авг. 30, 2024

Inflammation is thought to be an important mechanism for the development and progression of obesity-related heart failure with preserved ejection fraction (HFpEF). In STEP-HFpEF Program, once-weekly 2.4 mg semaglutide improved failure-related symptoms, physical limitations, exercise function, reduced levels C-reactive protein (CRP), a biomarker inflammation, body weight in participants HFpEF. However, neither prevalence nor clinical characteristics patients who have various magnitudes inflammation context HFpEF been well described. Furthermore, whether beneficial effects on HF efficacy endpoints Program are modified by baseline has not fully established. Finally, relationship between reduction changes CRP across defined.

Язык: Английский

---

Underpinnings of Heart Failure With Preserved Ejection Fraction in Women - From Prevention to Improving Function. A Co-publication With the American Journal of Preventive Cardiology and the Journal of Cardiac Failure

Journal of Cardiac Failure, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Innovations in heart failure management: The role of cutting-edge biomarkers and multi-omics integration

Journal of Molecular and Cellular Cardiology Plus, Год журнала: 2025, Номер 11, С. 100290 - 100290

Опубликована: Март 1, 2025

Heart failure (HF) remains a major cause of morbidity and mortality worldwide represents challenge for diagnosis, prognosis treatment due to its heterogeneity. Traditional biomarkers such as BNP NT-proBNP are valuable but insufficient capture the complexity HF, especially phenotypes HF with preserved ejection fraction (HFpEF). Recent advances in multi-omics technology novel cell-free DNA (cfDNA), microRNAs (miRNAs), ST2 galectin-3 offer transformative potential management. This review explores integration these innovative into clinical practice highlights their benefits, improved diagnostic accuracy, enhanced risk stratification non-invasive monitoring capabilities. By leveraging approaches, including lipidomics metabolomics, clinicians can uncover new pathways, refine classification phenotypes, develop personalized therapeutic strategies tailored individual patient profiles. Remarkable proteomics metabolomics have identified associated key mechanisms mitochondrial dysfunction, inflammation fibrosis, paving way targeted therapies early interventions. Despite promising results, significant challenges remain translating findings routine care, high costs, technical limitations need large-scale validation studies. report argues an integrative, multi-omics-based model overcome obstacles emphasizes importance collaboration between researchers, policy makers. linking science practical applications, approaches redefine management lead better outcomes more sustainable healthcare systems.

Язык: Английский

---

Myeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial

Heart Failure Reviews, Год журнала: 2025, Номер unknown

Опубликована: Фев. 25, 2025

Язык: Английский

---

Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin

JACC Heart Failure, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Inflammation may play an important pathophysiological role in the development and progression of heart failure (HF). Interleukin (IL)-6 is a circulating cytokine main regulator release C-reactive protein (CRP). The authors examined association between IL-6 high-sensitivity (hs)-CRP outcomes patients with HFrEF DAPA-HF trial their relationship effect dapagliflozin. Inclusion criteria included: 1) NYHA functional class II-IV; 2) left ventricular ejection fraction ≤40%; 3) elevated N-terminal pro-B-type natriuretic peptide; 4) estimated glomerular filtration rate ≥30 mL/min/1.73 m2. primary outcome was composite worsening HF event or cardiovascular death. hs-CRP were measured at baseline 12 months (Roche Diagnostics). associations adjusted for known prognostic variables, including NT-proBNP. Among 2,940 patients, median 6.01 pg/mL (Q1-Q3: 4.18-9.28 pg/mL) 2.05 mg/L 0.83-4.9 mg/L), respectively. Baseline tertiles (T) were: T1 ≤4.72 pg/mL; T2 4.73-7.89 T3 ≥7.90 pg/mL. risks relative to as follows: = HR 1.34 (95% CI: 1.04-1.73) 1.80 1.41-2.31). A rise associated worse outcomes. beneficial dapagliflozin on consistent regardless concentration (continuous interaction P 0.57), similar results hs-CRP. Dapagliflozin did not reduce months. In DAPA-HF, levels each risk reduced adverse (Study Evaluate Effect Incidence Worsening Heart Failure Cardiovascular Death Patients With Chronic [DAPA-HF]; NCT03036124).

Язык: Английский

---

CALLY Index as a Comprehensive Biomarker for Heart Failure Risk: Findings from NHANES 1999–2010

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Янв. 31, 2025

Background Heart failure (HF) is a critical global health issue characterized by high morbidity, mortality, and economic burden. The interplay of chronic inflammation, malnutrition, immune dysregulation central to HF pathogenesis. C-reactive protein-Albumin-Lymphocyte (CALLY) index, composite biomarker that integrates inflammatory, nutritional, parameters, offers novel, holistic approach risk prediction. However, its association with prevalence potential clinical utility remains underexplored. Methods This study utilized data from the NHANES 1999–2010 cohort, encompassing 14,900 participants after stringent inclusion criteria. CALLY index was computed as albumin (g/L) × lymphocyte count (10⁹/L) / protein (CRP, mg/L). Logistic regression models were assess relationship between quartiles prevalence, adjustments made for demographic, socioeconomic, factors. Nonlinear associations examined using restricted cubic spline analysis, while subgroup analyses evaluated differences across age, gender, ethnicity. Results Participants (n = 659, 4.4%) exhibited significantly lower values compared those without HF. Multivariate revealed robust, dose-dependent higher (Q4 vs. Q1: adjusted OR 7.49, 95% CI: 5.89–9.52, P < 0.001). Restricted analysis identified threshold value 692, above which sharply increased. Subgroup highlighted significant heterogeneity, stronger observed among older adults (≥ 60 years), males, non-Hispanic Black populations, suggesting demographic-specific predictive utility. Conclusions serves low-cost, readily accessible stratification, integrating dimensions nutrition, function. Its nonlinear offer practical insights early detection intervention. Tailored strategies high-risk demographic groups, such individuals, could enhance application. Further longitudinal studies interventional trials are required confirm these findings evaluate broader applicability in cardiovascular management.

Язык: Английский

---

Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure

American Journal of Preventive Cardiology, Год журнала: 2025, Номер unknown, С. 100928 - 100928

Опубликована: Фев. 1, 2025

Язык: Английский

---

Sex difference in the association between metabolic syndrome and the risk of stroke: a systematic review and meta-analysis

Frontiers in Neurology, Год журнала: 2025, Номер 16

Опубликована: Июнь 4, 2025

Background Metabolic syndrome comprises multiple cardiovascular risk factors, and previous studies have confirmed a significant association between metabolic an increased of stroke. However, no systematic meta-analysis has evaluated the sex differences in relationship This study aimed to investigate difference Methods The PubMed, Embase, Cochrane Library databases were systematically searched for eligible until October 2024. stroke was calculated by relative ratio (RRR) with 95% confidence interval (CI) using random-effects model inverse variance weighting. Results Nine involving 61,060 individuals included meta-analysis. No observed (RRR: 0.92; CI: 0.72–1.17; p = 0.482). Sensitivity analysis found that this stable. Subgroup analyses revealed male had greater than female follow-up duration &lt;10.0 years 0.70; 0.46–1.04; 0.078) low quality 0.54; 0.30–0.98; 0.043). Conclusion Sex may exist stroke, especially shorter periods. Further large prospective should be performed verify

Язык: Английский

---

Guideline-Optimised Treatment in Heart Failure—Do Higher Doses Reduce Systemic Inflammation More Significantly?

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(11), С. 3056 - 3056

Опубликована: Май 23, 2024

Background: Chronic inflammation is a constant phenomenon which accompanies the heart failure pathophysiology. In all phenotypes of failure, irrespective ejection fraction, there permanent low-grade activation and synthesis proinflammatory cytokines. Many classes anti-remodelling medication used in treatment chronic have been postulated to an anti-inflammatory effect. Methods: This retrospective study enrolled 220 patients focused on evaluating effect most active substances from these reducing level inflammatory biomarkers (C reactive protein, erythrocyte sedimentation rate fibrinogen) after initiation or up-titration. Our research if this intensifies while raising dose. The evaluation was performed at two visits with interval between them 6 months. Results: From beta-blockers class, carvedilol showed reduction (ESR), low (6.25 mg, bi daily) medium (12.5 doses. At same time, sacubitril/valsartan CRP levels. obtained only (49/51 high (97/103 doses, maximum being observed Conclusions: evaluated, significant ESR levels doses values cases ARNI.

Язык: Английский

---

Biomarkers in Heart Failure with Preserved Ejection Fraction: A Perpetually Evolving Frontier

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(16), С. 4627 - 4627

Опубликована: Авг. 7, 2024

Heart failure with preserved ejection fraction (HFpEF) represents a complex clinical syndrome, often very difficult to diagnose using the available tools. As global burden of this disease is constantly growing, surpassing prevalence heart reduced fraction, during last few years, efforts have focused on optimizing diagnostic and prognostic pathways an immense panel circulating biomarkers. After paradigm HFpEF development emerged more than 10 years ago, suggesting impact multiple comorbidities myocardial structure function, several phenotypes been characterized, attempt find ideal biomarker for each distinct pathophysiological pathway. Acknowledging limitations natriuretic peptides, hundreds potential biomarkers evaluated, some them demonstrating encouraging results. Among these, soluble suppression tumorigenesis-2 reflecting remodeling, growth differentiation factor 15 as marker inflammation albuminuria result kidney dysfunction or, recently, microRNAs proved their incremental value. number emerging in rapidly expanding, review, we aim explore most promising linked key mechanisms HFpEF, outlining utility diagnosis, risk stratification population screening, well limitations.

Язык: Английский

---